Related Experiment Videos
Respiratory pharmacology. Anticholinergic agents
Clinics in Chest Medicine
|September 1, 1986
Summary
Anticholinergic respiratory drugs, though old, are seeing a resurgence with newer derivatives like ipratropium. These agents show promise for treating bronchospastic diseases effectively.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Drug Development
Background:
- Anticholinergic agents represent an old class of respiratory medications.
- Their clinical use has been limited in recent years.
- Emerging evidence suggests potential for newer derivatives in respiratory therapy.
Purpose of the Study:
- To review the pharmacology of anticholinergic agents.
- To highlight the therapeutic potential of novel anticholinergic drugs.
- To emphasize the specific role of ipratropium in treating bronchospastic diseases.
Main Methods:
- Literature review of anticholinergic pharmacology.
- Analysis of clinical applications in respiratory diseases.
- Focus on ipratropium's mechanism and efficacy.
Main Results:
- Older anticholinergics have seen infrequent use.
- Newer anticholinergic derivatives demonstrate significant therapeutic value.
- Ipratropium is a key agent in managing bronchospastic conditions.
Conclusions:
- Anticholinergic agents, particularly newer ones like ipratropium, are valuable in treating bronchospastic diseases.
- Further research into anticholinergic pharmacology can optimize respiratory care.
- These drugs offer a viable treatment option for patients with obstructive airway diseases.